|
業務類別
|
Biotechnology |
|
業務概覽
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
| 公司地址
| 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041 |
| 電話號碼
| +1 650 200-0412 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.altoneuroscience.com |
| 員工數量
| 68 |
| Mr. Michael Conick Hanley, Jr |
Chief Operating Officer |
美元 488.80K |
26/03/2026 |
| Mr. Adam Savitz, M.D.,PhD |
Chief Medical Officer |
-- |
26/03/2026 |
| Mr. Nicholas Conrad Smith |
Chief Business Officer, Chief Financial Officer and Principal Accounting Officer |
美元 493.72K |
26/03/2026 |
| Dr. Amit Etkin, M.D.,PhD |
President, Chief Executive Officer and Chairman of the Board |
美元 650.67K |
26/03/2026 |
|
|
| Ms. Gwill York |
Independent Director |
26/03/2026 |
| Mr. Christopher Nixon Cox |
Lead Independent Director |
26/03/2026 |
| Mr. Andrew Dreyfus |
Independent Director |
26/03/2026 |
| Dr. Ramiro Sanchez, M.D. |
Independent Director |
26/03/2026 |
| Dr. Amit Etkin, M.D.,PhD |
President, Chief Executive Officer and Chairman of the Board |
26/03/2026 |
| Dr. Husseini Manji, M.D. |
Independent Director |
26/03/2026 |
|
|
|
|
